ArticleJournal of Crohn's & colitis2025
Disparities in Gender and Race Representation Among Authors of Inflammatory Bowel Disease Clinical Trials.
Article in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsFemale physicians, particularly those from minority populations, are significantly underrepresented in research authorship in gastroenterology. This underrepresentation negatively impacts their career progression. This study analyses gender and race representation trends in published clinical trials in inflammatory bowel disease (IBD) and associated factors.
methodsInflammatory bowel disease clinical trials were identified from ClinicalTrials.gov and www.ibd-eii.com, spanning the years 1955 to 2023. The variable gender was extracted for all authors and race was extracted for first, second, senior, corresponding authors, and principal investigator (PI) using predictive tools and manual verification. Data on authorship, trial characteristics, and sponsorship were collected.
resultsA total of 438 clinical trials involving 5517 authors were analyzed. Females constituted 26.3% of authors, 17.1% of first authors, 6.1% of senior authors, and 24.2% of PIs, with nonwhite individuals representing 12.3% of first authors, 5.9% of senior authors, and 18.8% of PIs. Female representation increased from 1971 to 2023 but remained substantially lower relative to male representation. Industry-sponsored trials had the lowest female author and PI representation while nonindustry, single-center, pediatric, and advanced therapy trials had higher female representation.
conclusionsThis study highlights persistent gender and racial disparities in IBD trial authorship and leadership despite some progress over the decades. Female and nonwhite individuals remain underrepresented, especially in industry-sponsored trials and in senior authorship roles. Systemic interventions are warranted to foster an inclusive and equitable research environment, including mentorship and support for underrepresented groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.